Leuprolide (Lupron, Eligard)

Overview

Leuprolide (also known as leuprorelin; brand names Lupron, Lupron Depot, Eligard, Fensolvi) is a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) classified as a GnRH superagonist. Developed by Takeda Pharmaceutical Company and first approved by the FDA in 1985 for advanced prostate cancer, leuprolide has become one of the most widely used hormonal agents in medicine, with FDA-approved indications spanning oncology, gynecology, and pediatric endocrinology [1][2][3].

The peptide is chemically designated as des-Gly¹⁰-[D-Leu⁶]-LH-RH ethylamide, with the sequence pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt and a molecular weight of 1209.4 Da (C₅₉H₈₄N₁₆O₁₂) [1][2]. Two critical structural modifications distinguish it from native GnRH (a decapeptide): substitution of glycine at position 6 with D-leucine and replacement of the C-terminal Gly¹⁰-NH₂ with a proline-ethylamide group. These modifications confer approximately 15- to 20-fold greater receptor binding affinity and dramatically increase proteolytic resistance, extending the circulating half-life from 3-4 minutes (native GnRH) to approximately 3 hours [1][2][13].

Leuprolide's pharmacological paradox is central to its clinical utility: while a single dose stimulates gonadotropin release (the "flare" effect), continuous or depot administration causes progressive downregulation of pituitary GnRH receptors, ultimately suppressing LH, FSH, and gonadal sex steroid production to castrate levels — a process often termed "chemical castration" or "medical castration" [2][9][13].

Type

GnRH superagonist (nonapeptide)

Molecular Weight

1209.4 Da (free base)

Molecular Formula

C₅₉H₈₄N₁₆O₁₂

Sequence

pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt

Modifications vs Native GnRH

D-Leu⁶ substitution; Pro⁹-ethylamide (des-Gly¹⁰)

Half-life

~3 hours (vs 3–4 min for native GnRH)

Potency vs Native GnRH

~15–20× more potent

Routes

IM (Lupron Depot), SC (Eligard, Fensolvi), SC daily injection

FDA First Approval

1985 (Lupron injection for prostate cancer)

Key Depot Formulations

1-month, 3-month, 4-month, 6-month

Molecular Pharmacology

Structure-Activity Relationships

Native GnRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂) is rapidly degraded by endopeptidases that cleave primarily at the Gly⁶-Leu⁷ and Pro⁹-Gly¹⁰ bonds. The two modifications in leuprolide address both vulnerable sites [10][13]:

1. D-Leu⁶ substitution: Replacing the achiral glycine at position 6 with D-leucine creates a stereochemical mismatch that prevents endopeptidase recognition at this cleavage site. The D-amino acid also enhances receptor binding by stabilizing a beta-turn conformation favored by the GnRH receptor
2. Pro⁹-ethylamide (des-Gly¹⁰): Deleting glycine-10 and converting proline-9 to an ethylamide eliminates the C-terminal cleavage site while maintaining the amide functionality essential for receptor binding

These modifications yield a molecule with ~20-fold greater potency than native GnRH and a plasma half-life roughly 50 times longer [1][13].

Mechanism of Action: The Agonist-to-Suppressor Paradox

Leuprolide's mechanism reflects the fundamental biology of pulsatile versus continuous GnRH signaling first described by Belchetz, Knobil, and colleagues [9]:

Phase 1 — Initial Stimulation (Days 1–7): Upon first administration, leuprolide binds to GnRH type I receptors (GnRH-R) on anterior pituitary gonadotrophs, coupling to Gq/11 proteins and activating the phospholipase C-beta cascade. This triggers IP3-mediated calcium release and DAG-activated protein kinase C signaling, causing exocytosis of stored LH and FSH. The result is a transient surge in gonadotropins and consequent rises in testosterone (in males) or estradiol (in females) — the so-called "flare" or "clinical flare" [2][7][10].

In men with prostate cancer, testosterone levels may increase to >600 ng/dL during the first week, potentially exacerbating bone pain, urinary obstruction, or spinal cord compression [7].

Phase 2 — Receptor Desensitization (Days 7–21): Continuous (non-pulsatile) receptor occupancy by leuprolide triggers homologous desensitization through multiple mechanisms [10][13]:

• GnRH receptor internalization and lysosomal degradation
• Downregulation of GnRH-R mRNA expression (to 35–50% of baseline by 2–4 weeks)
• Uncoupling of receptors from Gq/11 G proteins
• Depletion of intracellular calcium stores and PKC isoforms
• Impaired gonadotropin subunit gene transcription (LH-beta, FSH-beta, alpha-subunit)

Phase 3 — Sustained Suppression (Week 3 onward): By approximately 2–4 weeks of continuous leuprolide exposure, serum testosterone falls to castrate levels (<50 ng/dL, often <20 ng/dL), and estradiol falls to postmenopausal levels (<20 pg/mL). This suppression is maintained for the duration of treatment and is reversible upon discontinuation, though testosterone recovery may take 4–24 weeks depending on treatment duration and formulation [2][4][14].

Pharmacokinetics

Following subcutaneous injection of the daily formulation, leuprolide is rapidly absorbed with peak plasma concentrations at ~4 hours. The depot formulations (Lupron Depot, Eligard) provide sustained release through biodegradable polymer microsphere technology or the ATRIGEL delivery system, maintaining therapeutic drug levels for 1–6 months depending on formulation [24][25].

Leuprolide is metabolized by peptidases in the plasma and tissues. No active metabolites have been identified. Renal elimination accounts for approximately 5% of unchanged drug. Dose adjustment is not required for hepatic or renal impairment [24].

Formulations and Delivery Systems

Lupron Depot (IM Microsphere Technology)

Lupron Depot utilizes biodegradable poly(DL-lactide-co-glycolide) (PLGA) microspheres that encapsulate leuprolide acetate. Upon intramuscular injection, the microspheres form a depot from which leuprolide is released through polymer erosion and diffusion over the intended dosing interval [3][24]:

| Formulation | Dose | Indication | Duration | |-------------|------|------------|----------| | Lupron Depot | 7.5 mg | Prostate cancer | 1 month | | Lupron Depot | 22.5 mg | Prostate cancer | 3 months | | Lupron Depot | 30 mg | Prostate cancer | 4 months | | Lupron Depot | 45 mg | Prostate cancer | 6 months | | Lupron Depot | 3.75 mg | Endometriosis / fibroids | 1 month | | Lupron Depot | 11.25 mg | Endometriosis / fibroids | 3 months | | Lupron Depot-PED | 7.5–15 mg | Precocious puberty | 1 month | | Lupron Depot-PED | 11.25–30 mg | Precocious puberty | 3 months |

Important: The different depot strengths are not interchangeable or additive. Each formulation has unique release characteristics tailored to its dosing interval [24].

Eligard (SC ATRIGEL Delivery System)

Eligard employs the ATRIGEL system — a solution of biodegradable poly(DL-lactide-co-glycolide) dissolved in the biocompatible solvent N-methyl-2-pyrrolidone (NMP). Upon subcutaneous injection, the NMP dissipates into surrounding tissue and the polymer precipitates, forming a solid biodegradable implant that releases leuprolide over 1, 3, 4, or 6 months [25]. Available strengths: 7.5 mg (1-month), 22.5 mg (3-month), 30 mg (4-month), and 45 mg (6-month).

Camcevi (Leuprolide Mesylate Injectable Emulsion)

In 2025, the FDA approved a 3-month formulation of leuprolide mesylate 21 mg (Camcevi 3-month) for palliative treatment of advanced prostate cancer, complementing the previously approved 6-month (42 mg) formulation. Camcevi uses a proprietary FluidCrystal injection depot technology that forms a liquid crystalline gel upon subcutaneous injection, providing sustained leuprolide release. In the pivotal trial, 97.9% of patients achieved castrate testosterone (at or below 50 ng/dL) from day 28 through day 168. The formulation is supplied as a ready-to-use prefilled syringe, offering convenience advantages over reconstitution-requiring depot formulations.

Fensolvi (SC for Pediatric Use)

Fensolvi, approved in 2020, is a 6-month subcutaneous leuprolide formulation (45 mg) specifically indicated for central precocious puberty in children, utilizing a polymer-based delivery system [3].

Daily Subcutaneous Injection

The original Lupron injection (5 mg/mL solution) is administered as 1 mg (0.2 mL) daily by subcutaneous injection. While largely superseded by depot formulations for chronic indications, the daily injection remains important in IVF protocols where precise timing control is essential [2][24].

Clinical Applications

Advanced Prostate Cancer

Leuprolide's principal oncologic application is androgen deprivation therapy (ADT) for advanced prostate cancer. The rationale traces to Huggins and Hodges' Nobel Prize-winning discovery (1941) that prostate cancer is androgen-dependent [11].

Efficacy: The pivotal 1984 Leuprolide Study Group trial demonstrated equivalence of leuprolide to diethylstilbestrol (DES) for metastatic prostate cancer, with comparable overall survival but a superior cardiovascular safety profile compared to DES [12]. Modern data confirm that depot leuprolide achieves castrate testosterone (<50 ng/dL) in >93% of patients and profound castration (<20 ng/dL) in approximately 85% [5][14].

Current role: Leuprolide-based ADT is used as [2][5]:

• Primary therapy for advanced/metastatic hormone-sensitive prostate cancer
• Adjuvant and neoadjuvant therapy with radiation for intermediate- and high-risk localized disease
• Combination partner with antiandrogens (bicalutamide, enzalutamide, apalutamide, darolutamide) or novel agents (abiraterone)
• Intermittent ADT protocols to reduce side effect burden

Endometriosis

Leuprolide depot (3.75 mg monthly or 11.25 mg every 3 months) creates a hypoestrogenic state that induces atrophy of endometrial implants and provides significant pain relief [1][8].

Add-back therapy: Because unopposed estrogen deprivation causes intolerable vasomotor symptoms and accelerated bone loss, leuprolide for endometriosis is combined with norethindrone acetate (5 mg daily) as "add-back" therapy. The Surrey and Hornstein 12-month study demonstrated that add-back therapy preserved bone density (leuprolide alone caused 6.3% bone loss at 52 weeks) without compromising pain relief [8]. Treatment duration with add-back should not exceed 12 months. Calcium supplementation (1000 mg/day elemental calcium) is recommended during treatment [8][24].

Uterine Fibroids

Leuprolide is used preoperatively (typically 3–6 months) to [2][24]:

• Reduce fibroid volume by 30–60%
• Correct iron-deficiency anemia related to menorrhagia
• Reduce intraoperative blood loss
• Facilitate less invasive surgical approaches

Fibroids regrow upon treatment cessation, so leuprolide is not used as definitive standalone therapy.

Central Precocious Puberty (CPP)

Leuprolide depot is a first-line treatment for central (gonadotropin-dependent) precocious puberty [20]. By suppressing premature HPG axis activation, it:

• Halts or reverses progression of secondary sexual characteristics
• Slows accelerated skeletal maturation to preserve adult height potential
• Addresses psychosocial concerns related to premature puberty

The 2009 consensus statement recommends initiating treatment in girls presenting before age 8 and boys before age 9 with progressive pubertal development and advanced bone age [20]. Treatment is discontinued at the appropriate age for normal puberty (typically 11 years in girls, 12 in boys).

In Vitro Fertilization (IVF)

Leuprolide plays a central role in controlled ovarian stimulation protocols for IVF [2]:

Long down-regulation protocol: Daily leuprolide (0.5–1.0 mg SC) begins in the mid-luteal phase of the preceding cycle. After 10–14 days of pituitary suppression (confirmed by low estradiol and thin endometrium), gonadotropin stimulation is initiated while continuing leuprolide at a reduced dose (0.25–0.5 mg). This prevents premature LH surges that would trigger premature ovulation and compromise egg retrieval.

Microdose flare protocol: Very low doses (40–80 micrograms twice daily) are started on cycle day 2–3, exploiting the initial flare effect to recruit additional follicles. This approach is preferred for older patients or poor responders whose ovaries benefit from the brief FSH/LH surge.

Lupron trigger: A single dose of leuprolide (1–4 mg) can replace hCG as the ovulation trigger in antagonist protocols, inducing an endogenous LH surge while reducing the risk of ovarian hyperstimulation syndrome (OHSS).

Premenopausal Breast Cancer

Leuprolide is used for ovarian function suppression (OFS) in premenopausal women with hormone receptor-positive breast cancer, typically combined with tamoxifen or an aromatase inhibitor [1]. Clinical trials (TEXT, SOFT) have demonstrated that OFS plus endocrine therapy improves disease-free survival in high-risk premenopausal patients. The 3-month depot (11.25 mg) provides equivalent ovarian suppression to monthly dosing.

Gender-Affirming Care

Leuprolide is one of the most commonly used puberty-suppressing agents in gender-affirming care for transgender and gender-diverse youth [21]. The Endocrine Society and the World Professional Association for Transgender Health (WPATH) guidelines recommend:

• Initiating puberty suppression at Tanner stage 2–3
• GnRH agonist therapy to pause endogenous puberty, allowing time for psychosocial maturation and consideration of gender-affirming hormone therapy
• Transition to cross-sex hormones around age 16 (with individual assessment)

Both Lupron Depot and Eligard have been studied in this population, with clinical puberty suppression achieved in the vast majority of patients [21].

Testosterone Flare: Clinical Significance and Management

The initial testosterone/estradiol flare is a class effect of all GnRH agonists and carries important clinical consequences [7]:

Clinical Consequences of Unmanaged Flare

In patients with advanced prostate cancer, the testosterone surge may cause:

• Worsening bone pain (most common)
• Ureteral or bladder outlet obstruction
• Spinal cord compression (in patients with vertebral metastases)
• Rarely, death from disease flare

Flare Prevention Strategies

Antiandrogen co-administration: The standard approach is to begin an antiandrogen 1–2 weeks before the first leuprolide injection and continue for 2–4 weeks after [7]:

• Bicalutamide 50 mg daily (most commonly used)
• Flutamide 250 mg three times daily
• Nilutamide 150 mg daily

GnRH antagonist alternative: Degarelix (Firmagon) and oral relugolix (Orgovyx) are GnRH receptor antagonists that suppress testosterone without any flare, making them preferred in patients with impending spinal cord compression, severe ureteral obstruction, or very high-volume metastatic disease [4][19].

Patient selection for flare protection [7]:

• Mandatory: Patients with impending cord compression, severe obstructive uropathy, or extensive symptomatic bone metastases
• Recommended: Patients with high PSA (>50 ng/mL) or widespread metastatic disease
• Optional: Patients with low-volume, asymptomatic disease

Comparison with Other GnRH Analogs

GnRH Agonists

| Feature | Leuprolide | Goserelin (Zoladex) | Triptorelin (Trelstar) | Histrelin (Vantas) | |---------|-----------|--------------------|-----------------------|-------------------| | Route | IM or SC injection | SC implant (abdomen) | IM injection | SC implant (arm) | | Depot options | 1, 3, 4, 6 months | 1, 3 months | 1, 3, 6 months | 12 months (implant) | | Injection pain | Moderate | Moderate (larger needle) | Moderate | Minor surgery for implant | | Castration rate (<50 ng/dL) | >93% | >95% | >95% | >98% | | Approved indications | Broadest (prostate, endometriosis, fibroids, CPP, IVF) | Prostate, breast, endometriosis | Prostate, CPP | Prostate, CPP | | Generic available | Yes (limited) | No | Yes (limited) | No |

A systematic review by Bolton and Lynch (2018) found all GnRH agonists comparably effective for testosterone suppression, though goserelin showed slightly better maintenance of castrate levels (<50 ng/dL) compared to leuprolide in some analyses [5].

GnRH Antagonists: Degarelix and Relugolix

GnRH antagonists competitively block the GnRH receptor without initial stimulation, providing key advantages [4][19]:

Degarelix (Firmagon):

• No testosterone flare
• Faster castration (96% within 3 days vs. ~3 weeks for leuprolide)
• Monthly SC injection only (no long-acting depot)
• Phase III data showed a trend toward fewer cardiovascular events versus leuprolide [19]

Relugolix (Orgovyx) — the HERO trial [4]:

• First oral GnRH antagonist (120 mg once daily)
• Superior sustained castration: 96.7% vs. 88.8% with leuprolide (p <0.0001)
• Rapid testosterone suppression: castrate levels by day 4 (vs. day 29 for leuprolide)
• 54% lower rate of major adverse cardiovascular events (2.9% vs. 6.2%)
• Rapid testosterone recovery after discontinuation (median 270.76 vs. 12.26 ng/dL at 90 days)
• Convenient oral dosing

The HERO trial has positioned relugolix as an important alternative to leuprolide, particularly for patients with pre-existing cardiovascular disease [4].

Adverse Effects and Safety

Vasomotor Symptoms

Hot flashes are the most common side effect, affecting 50–80% of patients across all indications. They result from estrogen/testosterone withdrawal affecting hypothalamic thermoregulation [2][24]. Management options include:

• Low-dose venlafaxine (37.5–75 mg daily)
• Gabapentin (300–900 mg daily)
• Medroxyprogesterone acetate (20 mg daily) in select patients

Bone Mineral Density Loss

Chronic sex steroid deprivation causes accelerated bone resorption [17][18]:

• Men on ADT: Bone mineral density (BMD) declines 2–3% per year at the lumbar spine during the first 1–2 years, with fracture risk increasing by approximately 20–45% over 5 years [17]
• Women with endometriosis: Leuprolide alone caused 6.3% BMD loss at 52 weeks; add-back therapy with norethindrone acetate largely prevents this [8]

Mitigation strategies:

• DEXA scan at baseline and annually during treatment
• Calcium supplementation (1200 mg/day) and vitamin D (800–1000 IU/day)
• Weight-bearing exercise
• Bisphosphonates (zoledronic acid 4 mg annually) or denosumab (60 mg every 6 months) for patients at high fracture risk [17][18]

Cardiovascular and Metabolic Risk

A landmark SEER-Medicare analysis by Keating et al. (2006) identified increased risks during GnRH agonist therapy [15]:

• Incident diabetes: adjusted HR 1.44
• Coronary heart disease: adjusted HR 1.16
• Myocardial infarction: adjusted HR 1.11
• Sudden cardiac death: elevated risk

The 2010 AHA/ACS/AUA science advisory acknowledged these risks and recommended cardiovascular risk factor screening and management before initiating ADT [16].

Proposed mechanisms [6][22][23]:

• Insulin resistance and hyperglycemia from lean mass loss and fat mass gain
• Dyslipidemia (increased LDL cholesterol and triglycerides)
• Increased arterial stiffness
• QTc prolongation (FDA black box warning)
• GnRH agonist-specific promotion of atherosclerotic plaque instability (demonstrated in ApoE-knockout mice — an effect not seen with the GnRH antagonist degarelix) [23]

Notably, the HERO trial showed that the oral GnRH antagonist relugolix was associated with a 54% reduction in major adverse cardiovascular events compared to leuprolide, suggesting that part of the cardiovascular risk may be a class-specific effect of GnRH agonists rather than a consequence of testosterone suppression alone [4][22].

Metabolic Syndrome

ADT with leuprolide promotes a constellation of metabolic changes resembling metabolic syndrome [18]:

• Decreased lean body mass (2–4% in the first year)
• Increased total body fat (8–10% in the first year)
• Increased waist circumference
• Elevated fasting glucose and HbA1c
• Elevated triglycerides and LDL cholesterol

Other Adverse Effects

• Musculoskeletal: Arthralgia, myalgia, general pain
• Neuropsychiatric: Mood changes, depression, fatigue, cognitive impairment ("brain fog")
• Sexual: Loss of libido, erectile dysfunction, gynecomastia
• Injection site: Pain, erythema, induration (depot formulations)
• Rare but serious: Pituitary apoplexy (extremely rare), severe cutaneous adverse reactions, anaphylaxis
• Pediatric-specific: Monitor for pseudotumor cerebri (idiopathic intracranial hypertension) and psychiatric events [20][24]

Detailed Pharmacokinetics

Absorption by Route and Formulation

Daily subcutaneous injection (Lupron injection, 5 mg/mL):

• Bioavailability: approximately 90% following SC administration
• Time to peak concentration (Tmax): approximately 4 hours
• Peak plasma concentration (Cmax) after 1 mg SC: approximately 20 ng/mL
• Terminal half-life: approximately 3 hours (vs. 3-4 minutes for native GnRH)
• Clearance: approximately 7.6 L/hour (systemic clearance via peptidase degradation)
• Volume of distribution: approximately 27 L (0.4 L/kg), indicating extravascular tissue distribution [24]

Lupron Depot (PLGA microsphere IM injection): The depot formulations use poly(DL-lactide-co-glycolide) (PLGA) microspheres that provide sustained release through polymer hydration, degradation, and erosion [3][24]:

• 1-month depot (7.5 mg): Initial burst release produces serum levels of approximately 20 ng/mL within 4-8 hours, declining to approximately 0.3-0.5 ng/mL by 2 weeks, then plateau at approximately 0.2-0.4 ng/mL through day 28. Castrate testosterone achieved by approximately day 21 in greater than 93% of patients.
• 3-month depot (22.5 mg): Initial burst of approximately 36 ng/mL at 4-8 hours, with sustained trough concentrations of approximately 0.2-0.8 ng/mL maintained for 84 days. The PLGA microsphere composition is optimized for slower initial erosion and more extended plateau.
• 4-month depot (30 mg): Burst release followed by sustained trough concentrations maintaining testosterone suppression for 112 days.
• 6-month depot (45 mg): The longest-acting formulation. Initial peak followed by biphasic decline and then extended plateau at 0.1-0.5 ng/mL for approximately 168 days. Uses a higher lactide-to-glycolide ratio in the PLGA polymer for slower degradation kinetics [24].

The release kinetics of all depot formulations follow a general pattern: (1) initial burst from surface-adsorbed drug (hours), (2) lag phase as polymer hydrates (days to 1-2 weeks), and (3) sustained release through bulk erosion (weeks to months). Different depot strengths are NOT interchangeable or additive -- each has unique polymer composition and release characteristics [24].

Eligard (ATRIGEL SC delivery system): The ATRIGEL system uses PLGA dissolved in N-methyl-2-pyrrolidone (NMP). Upon subcutaneous injection, NMP dissipates into tissue, and the polymer precipitates to form a solid biodegradable implant in situ [25].

• Absorption profile differs from Lupron Depot, with generally slower initial burst and more uniform sustained release
• Available in 1-month (7.5 mg), 3-month (22.5 mg), 4-month (30 mg), and 6-month (45 mg) formulations
• Serum leuprolide concentrations at steady state are comparable to Lupron Depot for equivalent dosing intervals

Metabolism and Elimination

Leuprolide is metabolized by peptidases in the plasma and tissues to smaller inactive peptide fragments. No pharmacologically active metabolites have been identified. Metabolism does not involve cytochrome P450 enzymes [24].

Renal elimination accounts for approximately 5% of unchanged drug. The predominant elimination pathway is peptidase-mediated degradation. No dose adjustment is required for hepatic or renal impairment [24][25].

Special Population PK

• Elderly (greater than 65): No significant PK differences; however, age-related decline in renal function may marginally reduce clearance of peptide fragments
• Pediatric (CPP): PK in children aged 2-9 years is generally similar on a weight-adjusted basis; depot formulations maintain adequate suppression in the majority of patients
• Obese patients: Weight-based dosing is not used for depot formulations (fixed-dose products); obese patients may have modestly higher leuprolide clearance, but testosterone suppression rates remain above 90%
• Hepatic/renal impairment: No dose adjustment required

Testosterone Suppression: Dose-Response

Dose-Response by Formulation

The clinical efficacy of leuprolide is measured primarily by the degree and reliability of testosterone suppression:

Testosterone suppression to castrate levels (below 50 ng/dL):

• 1-month depot (7.5 mg): Achieves castration in greater than 93% of patients by day 21-28 [5][14]
• 3-month depot (22.5 mg): Achieves castration in 92-97% of patients by month 2, maintained through month 3 [5]
• 4-month depot (30 mg): Achieves castration in 93-98% of patients, maintained through month 4
• 6-month depot (45 mg): Achieves castration in 93-96% of patients, maintained through month 6 [24]

Profound castration (below 20 ng/dL):

• Approximately 80-85% of patients across all depot formulations achieve testosterone below 20 ng/dL at steady state
• This more stringent threshold is increasingly advocated based on data suggesting improved outcomes in prostate cancer
• Patients not achieving profound castration may benefit from switching to a GnRH antagonist

Testosterone flare kinetics:

• Days 1-3: Testosterone rises by approximately 40-80% above baseline (may exceed 600 ng/dL in men with baseline values above 400)
• Days 3-7: Peak testosterone flare (approximately 150-200% of baseline in some patients)
• Days 7-14: Testosterone begins declining as receptor desensitization occurs
• Days 14-21: Testosterone approaches castrate levels
• Day 21-28: Greater than 93% of patients at below 50 ng/dL

Testosterone recovery after discontinuation:

• Testosterone recovery is variable and depends on treatment duration and patient age
• Short-term treatment (3-6 months): Recovery to greater than 250 ng/dL within 4-12 weeks
• Long-term treatment (greater than 2 years): Recovery may take 4-24 weeks; approximately 10-15% of men over 65 may not fully recover
• Young women (IVF/endometriosis): Estradiol recovery typically within 6-12 weeks of last depot injection

Dose-Response in Endometriosis

Leuprolide creates a hypoestrogenic state with estradiol levels below 20 pg/mL [8]:

• 3.75 mg monthly: Achieves estradiol suppression below 20 pg/mL in approximately 90% of women within 4-8 weeks
• 11.25 mg 3-month: Equivalent estradiol suppression with improved compliance
• Pain reduction: Approximately 80-85% of patients achieve significant pain relief by month 2
• Bone density change: Without add-back, BMD declines 3-6% at the lumbar spine over 6 months; add-back therapy (norethindrone 5 mg daily) limits loss to approximately 1% [8]

Dose-Response in Central Precocious Puberty

• LH suppression (stimulated LH below 4 IU/L): Achieved in greater than 95% of children on appropriate weight-based depot dosing [20]
• Bone age advancement rate: Normalized (ratio of bone age to chronological age advancement decreasing toward 1.0) within 6-12 months
• Predicted adult height gain: Approximately 4-6 cm on average with treatment for 2-4 years before physiologic puberty age

Comparative Effectiveness

Leuprolide vs. Goserelin (Zoladex)

A systematic review by Bolton and Lynch (2018) comparing GnRH agonists for prostate cancer found [5]:

| Outcome | Leuprolide | Goserelin | Difference | |---------|-----------|-----------|------------| | Castration rate (below 50 ng/dL) | Greater than 93% | Greater than 95% | Slight advantage goserelin | | Profound castration (below 20 ng/dL) | ~85% | ~87% | Slight advantage goserelin | | Testosterone breakthroughs | 5-13% | 2-4% | Lower with goserelin | | Available depot durations | 1, 3, 4, 6 months | 1, 3 months | More options with leuprolide | | Route | IM or SC | SC implant (abdomen) | Different | | Approved indications | Broadest | Prostate, breast, endometriosis | More indications for leuprolide |

Goserelin demonstrated marginally better maintenance of castrate levels with fewer testosterone breakthroughs above 50 ng/dL, though this did not translate into proven clinical outcome differences [5].

Leuprolide vs. Triptorelin (Trelstar)

Triptorelin is a GnRH agonist with similar efficacy profile to leuprolide:

• Castration rates: comparable (greater than 93% for both)
• Available in 1-month (3.75 mg), 3-month (11.25 mg), and 6-month (22.5 mg) depots
• Triptorelin uses a different PLGA microsphere formulation (Pamorelin/Decapeptyl outside the US)
• No head-to-head trials demonstrating superiority of either agent
• Both are considered interchangeable in clinical practice for prostate cancer

Leuprolide vs. Degarelix (GnRH Antagonist)

Degarelix (Firmagon) represents a mechanistically distinct approach [19]:

| Outcome | Leuprolide Depot | Degarelix 240/80 mg | Clinical Significance | |---------|-----------------|-------------------|---------------------| | Testosterone flare | Present (days 1-7) | None | Critical in high-risk patients | | Time to castration | ~21 days | 3 days (96% by day 3) | Much faster with degarelix | | Castration at 1 year | 88-97% | 97% | Slight advantage degarelix | | PSA progression-free survival | Reference | HR 0.64 in post-hoc subgroup | Possible advantage degarelix | | Cardiovascular events | 6.2% (HERO, leuprolide arm) | Trend toward fewer (Klotz 2008) | Possible advantage degarelix | | Musculoskeletal events | 10-15% | 10-12% | Similar | | Injection site reactions | 2-5% | 35-40% (initial 240 mg dose) | Much more common with degarelix | | Depot duration | Up to 6 months | 1 month only | Convenience advantage leuprolide |

Leuprolide vs. Relugolix (Oral GnRH Antagonist)

The HERO trial (n = 934) provided the most direct comparison [4]:

| Outcome | Leuprolide 22.5 mg q3mo | Relugolix 120 mg PO daily | p-value | |---------|------------------------|--------------------------|---------| | Sustained castration (48 wk) | 88.8% | 96.7% | p below 0.0001 | | Castrate testosterone by day 4 | ~5% | 56% | - | | Castrate testosterone by day 15 | ~70% | 98.7% | - | | Major adverse CV events | 6.2% | 2.9% | 54% lower with relugolix | | FSH suppression (48 wk) | ~71% below LLN | ~85% below LLN | Advantage relugolix | | Testosterone recovery (90 days post-stop) | Median 12.3 ng/dL | Median 270.8 ng/dL | Much faster recovery | | Hot flashes | 52% | 46% | Similar | | Fatigue | 26% | 22% | Similar |

Relugolix demonstrated superior sustained castration, faster onset, faster testosterone recovery, and significantly fewer cardiovascular events. It has been positioned as the preferred option for patients with pre-existing cardiovascular disease [4][22].

Enhanced Adverse Effect Profile

Quantitative Adverse Event Rates from Pivotal Trials and Post-Marketing Surveillance

| Adverse Event | Incidence | Duration-Dependence | Notes | |---------------|-----------|-------------------|-------| | Hot flashes | 50-80% | Persistent during treatment | Most common; manage with venlafaxine/gabapentin | | Injection site reactions | 2-8% | Per injection | Pain, erythema, induration | | Fatigue | 20-30% | Persistent | Often underreported | | Headache | 15-25% | Early treatment | May resolve | | Erectile dysfunction | 40-70% | Persistent during treatment | Expected consequence of castration | | Loss of libido | 50-80% | Persistent during treatment | Expected | | Gynecomastia/breast tenderness | 5-10% | Variable | More common with longer treatment | | Depression/mood changes | 10-20% | Variable | Screen regularly | | Cognitive impairment | 10-25% | Progressive with duration | "Chemo brain"; partially reversible | | BMD loss (lumbar spine, annual) | 2-3% per year | Progressive | DEXA at baseline and annually | | Fracture risk increase (5 yr) | 20-45% | Progressive | Bisphosphonate/denosumab if high risk | | New diabetes | HR 1.44 | Progressive | Monitor fasting glucose/HbA1c [15] | | Coronary heart disease | HR 1.16 | Progressive | Cardiovascular screening recommended [15] | | MI | HR 1.11 | Progressive | AHA/ACS/AUA advisory [16] | | QTc prolongation | 5-10% | Variable | ECG monitoring; avoid QT drugs | | Weight gain (lean mass loss / fat gain) | 8-10% fat increase | Progressive (year 1) | Exercise prescription [18] | | Arthralgia/myalgia | 10-20% | Variable | Symptomatic management | | Anemia | 5-10% | Progressive | Monitor CBC | | Testosterone flare symptoms | 10-20% (prostate cancer) | Transient (week 1-2) | Antiandrogen cover [7] | | Pituitary apoplexy | Extremely rare (below 0.01%) | Acute (first dose) | Reported in patients with pituitary macroadenomas |

Drug Interactions

• QT-prolonging drugs: Leuprolide-induced hypogonadism may prolong QTc; use caution with concurrent amiodarone, sotalol, fluoroquinolones, and azole antifungals
• Bicalutamide/enzalutamide/apalutamide: Commonly co-prescribed for combined androgen blockade; no PK interaction but additive pharmacodynamic effects on androgen axis
• Abiraterone acetate: Often combined with GnRH agonists; no PK interaction; CYP17 inhibition complements testicular suppression
• Corticosteroids: Concurrent use may compound metabolic syndrome risk (hyperglycemia, weight gain)
• Bisphosphonates/denosumab: Commonly co-prescribed to mitigate BMD loss; no interaction
• Drugs affecting pituitary function: Dopamine agonists (bromocriptine, cabergoline) may theoretically interact, though no clinically significant interaction documented
• Insulin/oral antidiabetics: Dose adjustment may be required due to ADT-induced insulin resistance

Regulatory and Development History

| Year | Milestone | |------|-----------| | 1971 | GnRH structure elucidated by Schally and Guillemin | | 1973 | Leuprolide first synthesized as a GnRH analog | | 1985 | Lupron injection (daily SC) approved by FDA for advanced prostate cancer | | 1989 | Lupron Depot (monthly IM) approved for prostate cancer | | 1990 | Lupron Depot approved for endometriosis and uterine fibroids | | 1993 | Lupron Depot-PED approved for central precocious puberty | | 1997 | 3-month Lupron Depot (22.5 mg) approved | | 2000 | Viadur (12-month leuprolide implant) approved (later discontinued) | | 2002 | Eligard (ATRIGEL subcutaneous system) approved | | 2011 | 6-month Lupron Depot (45 mg) approved for prostate cancer | | 2020 | Fensolvi (6-month SC depot for CPP) approved | | 2020 | Relugolix (oral GnRH antagonist) approved, providing first oral alternative | | 2025 | FDA approves 3-month leuprolide mesylate 21 mg (Camcevi 3-month) for advanced prostate cancer |

Lupron was developed through a joint venture between Takeda Chemical Industries and Abbott Laboratories (TAP Pharmaceuticals, 1985–2008). Marketing is currently led by AbbVie (succeeding Abbott) [3].

Clinical Evidence Summary

| Study / Source | Year | Design | Key Finding | |----------------|------|--------|-------------| | Leuprolide Study Group [12] | 1984 | Phase III RCT | Leuprolide equivalent to DES for metastatic prostate cancer with fewer cardiovascular events | | Surrey & Hornstein [8] | 1998 | 12-month clinical trial | Add-back norethindrone preserved BMD during leuprolide therapy for endometriosis (6.3% bone loss prevented) | | Keating et al. [15] | 2006 | SEER-Medicare cohort (73,196 men) | GnRH agonist ADT associated with increased diabetes (HR 1.44), CHD (HR 1.16), MI (HR 1.11) | | Bolton & Lynch [5] | 2018 | Systematic review | All GnRH agonists comparably effective; goserelin showed marginally better castration maintenance | | Shore et al. (HERO) [4] | 2020 | Phase III RCT (n=934) | Oral relugolix superior to leuprolide for sustained castration (96.7% vs. 88.8%) with 54% fewer MACE | | Gupta et al. [6] | 2021 | Review | Comprehensive analysis of CV toxicity mechanisms in ADT | | de Vries et al. [22] | 2023 | Systematic review/meta-analysis | GnRH antagonists associated with lower cardiovascular risk than GnRH agonists |

References

1. [1] (). . . DOI
2. [2] (). . .
3. [3] (). . . DOI
4. [4] (). . . DOI
5. [5] (). . . DOI
6. [6] (). . . DOI
7. [7] (). . .
8. [8] (). . . DOI
9. [9] (). . . DOI
10. [10] (). . . DOI
11. [11] (). . . DOI
12. [12] (). . . DOI
13. [13] (). . . DOI
14. [14] (). . . DOI
15. [15] (). . . DOI
16. [16] (). . . DOI
17. [17] (). . . DOI
18. [18] (). . . DOI
19. [19] (). . . DOI
20. [20] (). . . DOI
21. [21] (). . . DOI
22. [22] (). . . DOI
23. [23] (). . . DOI
24. [24] (). . .
25. [25] (). . .